Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Botulinum toxin type A in the treatment of Raynaud's phenomenon: A three-year follow-up study.

Medina S, Gómez-Zubiaur A, Valdeolivas-Casillas N, Polo-Rodríguez I, Ruíz L, Izquierdo C, Guirado C, Cabrera A, Trasobares L.

Eur J Rheumatol. 2018 Dec;5(4):224-229. doi: 10.5152/eurjrheum.2018.18013. Epub 2018 Oct 12.

2.

Botulinum toxin A treatment of Raynaud's phenomenon: a review.

Iorio ML, Masden DL, Higgins JP.

Semin Arthritis Rheum. 2012 Feb;41(4):599-603. doi: 10.1016/j.semarthrit.2011.07.006. Epub 2011 Aug 24. Review.

PMID:
21868066
3.

[Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].

Serri J, Legré R, Veit V, Guardia C, Gay AM.

Ann Chir Plast Esthet. 2013 Dec;58(6):658-62. doi: 10.1016/j.anplas.2011.11.001. Epub 2011 Dec 26. French.

PMID:
22204894
4.

Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review.

Żebryk P, Puszczewicz MJ.

Arch Med Sci. 2016 Aug 1;12(4):864-70. doi: 10.5114/aoms.2015.48152. Epub 2015 Jan 8.

5.

Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.

Colakoğlu M, Cobankara V, Akpolat T.

Ann Pharmacother. 2007 Sep;41(9):1544-7. Epub 2007 Jul 31.

PMID:
17666574
6.

The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.

Dhaliwal K, Griffin M, Denton CP, Butler PEM.

BMJ Case Rep. 2018 Mar 9;2018. pii: bcr-2017-219348. doi: 10.1136/bcr-2017-219348.

PMID:
29525756
7.

Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.

Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, Ishikawa O.

J Dermatol. 2016 Jan;43(1):56-62. doi: 10.1111/1346-8138.13030. Epub 2015 Jul 15.

PMID:
26173902
8.

Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.

Motegi SI, Uehara A, Yamada K, Sekiguchi A, Fujiwara C, Toki S, Date Y, Nakamura T, Ishikawa O.

Acta Derm Venereol. 2017 Jul 6;97(7):843-850. doi: 10.2340/00015555-2665.

9.

Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.

Fregene A, Ditmars D, Siddiqui A.

J Hand Surg Am. 2009 Mar;34(3):446-52. doi: 10.1016/j.jhsa.2008.11.026.

PMID:
19258141
10.

Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.

Zhao H, Lian Y.

Australas J Dermatol. 2015 Aug;56(3):202-5. doi: 10.1111/ajd.12326. Epub 2015 Mar 29.

PMID:
25817568
11.

Endoscopic thoracic sympathicotomy for Raynaud's phenomenon.

Matsumoto Y, Ueyama T, Endo M, Sasaki H, Kasashima F, Abe Y, Kosugi I.

J Vasc Surg. 2002 Jul;36(1):57-61.

12.

Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.

J Rheumatol. 1992 Sep;19(9):1407-14.

PMID:
1279170
13.

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.

Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.

Br J Rheumatol. 1998 Sep;37(9):952-60.

PMID:
9783759
14.

Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.

Chatterjee S.

Curr Treat Options Cardiovasc Med. 2010 Apr;12(2):185-204. doi: 10.1007/s11936-010-0065-x.

PMID:
20842555
15.

The diagnosis and treatment of Raynaud's phenomenon.

Porter JM, Snider RL, Bardana EJ, Rösch J, Eidemiller LR.

Surgery. 1975 Jan;77(1):11-23.

PMID:
1078555
16.

Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding.

Anderson JE, Held N, Wright K.

Pediatrics. 2004 Apr;113(4):e360-4.

PMID:
15060268
17.

A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.

Uppal L, Dhaliwal K, Butler PE.

J Hand Surg Eur Vol. 2014 Oct;39(8):876-80. doi: 10.1177/1753193413516242. Epub 2013 Dec 24.

PMID:
24369360
18.

Botox therapy for ischemic digits.

Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J, Gillespie JN, Bueno RA Jr, Cooney CM.

Plast Reconstr Surg. 2009 Jul;124(1):191-201. doi: 10.1097/PRS.0b013e3181a80576.

PMID:
19568080
19.

Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.

Kumar U, Sankalp G, Sreenivas V, Kaur S, Misra D.

Rheumatol Int. 2013 Apr;33(4):1047-52. doi: 10.1007/s00296-012-2466-5. Epub 2012 Jul 26. Erratum in: Rheumatol Int. 2013 Apr;33(4):1053. Gokhle, Sankalp S [corrected to Sankalp, Gokhale].

PMID:
22833239
20.

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM.

Rheumatology (Oxford). 2001 Sep;40(9):1038-43.

PMID:
11561116

Supplemental Content

Support Center